GI CANCERS

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

Chemotherapy may be avoidable for patients with stage II colon cancer, and circulating tumor DNA has demonstrated the ability to detect which patients, according to phase 2 study results.

The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct

Charles J. Schneider, MD, FACP, discusses the overall prognosis of patients with anal carcinoma.

The FDA has granted approval to nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

In an interview with Targeted Oncology, Ping Chi, discussed the novel strategy of combining KIT and MEK inhibition to treat patients with GIST treated in the frontline setting.

Although there was no significant overall survival benefit shown with pembrolizumab in the KEYNOTE-177 study, response and safety findings still support its use as a frontline option for patients with microsatellite instability high and mismatch repair deficient metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the differences between adagrasib and other KRAS inhibitors.

The FDA has granted priority review to a supplemental biologics license application for durvalumab as treatment of patients with locally advanced or metastatic biliary tract cancer.

The FDA has granted orphan drug designation to AB001 for the treatment of patients with pancreatic cancer and acute myeloid leukemia.

The FDA has granted breakthrough device designation to Precision-GI, a tool that assists with performing a tumor biopsy.

The first patient has been dosed in the phase 1 KN-4802 trial examining the safety, tolerability, and preliminary efficacy of KIN-3248 in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

The phase 2 HERIZON-BTC-01 of zanidatamab in patients with HER2-amplified biliary tract cancer has met its patient enrollment goal.

In RATIONALE 306, tislelizumab plus chemotherapy extended overall survival in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

CMG90 is the only drug in its class to have received fast-track status to date. Prior to its fast track status, the drug was granted orphan drug designation by the FDA.

In an interview with Targeted Oncology, Luv Hajirawala, MD, discussed the relevance of high-risk features in patients with stage III colon cancer, and how a recent real-world analysis may change risk stratification in the future.

Samuel J. Klempner, MD, discusses the mechanism of action of the investigational agent DKN-01 in patients with gastroesophageal adenocarcinoma.

Nitika Sharma, MD, explores developments in the esophageal cancer landscape for Esophageal Cancer Awareness Month.

The recent, significant advances for immunotherapy in esophageal and gastroesophageal junction cancer are promising, and oncologists hope it is just the beginning of further improvements in patient outcomes.

Treatment with nivolumab plus chemotherapy was more effective compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in the CheckMate 649 study.

According to 5-year survival data from the BILCAP study, capecitabine stands up to observation as a treatment strategy for patient with biliary tract cancer.

Several notable trials in colorectal cancer suggest a shift in treatment management, especially in the length of treatment with immunotherapies.

Samuel J. Klempner, MD, discusses unmet needs in patients with gastroesophageal adenocarcinoma when it comes to biomarker-targeted agents.